Drug profile

The FDA adverse-event record for No Active Ingredient Defined

27 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference No Active Ingredient Defined. See the species affected, top reactions, and outcomes below.

27
adverse-event reports
11.1%
death-coded share
Dog
most-reported species
8
Bloody diarrhoea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
3
Deaths Reported
11.1%
Death Rate

Active Ingredients

No Active Ingredient Defined

Administration Routes

UnknownOralTopical

Species Affected

Dog 27

Most Affected Breeds

Terrier - Black Russian 6
Retriever - Labrador 3
Chihuahua 3
Sheepdog - Long-haired Pyrenean 2
Dog (unknown) 2
Pug 2
Shepherd Dog - Australian 2
Sheepdog - Shetland 1
Irish Wolfhound 1
Chinese Crested Dog (unspecified) 1

Most Reported Reactions

Bloody diarrhoea 8
Lack of efficacy (ectoparasite) - flea 6
Seizure NOS 5
Lethargy (see also Central nervous system depression in Neurological) 4
Vomiting 4
Lack of efficacy - NOS 3
Cardiomyopathy 3
Agitation 3
Death by euthanasia 3
Itching 2
Diarrhoea 2
Other abnormal test result NOS 2

Outcome Breakdown

Ongoing
9 (33.3%)
Outcome Unknown
8 (29.6%)
Recovered/Normal
7 (25.9%)
Euthanized
3 (11.1%)

No Active Ingredient Defined Adverse Event Insights

27 reports name No Active Ingredient Defined; 3 recorded a death outcome (11.1% of reported events, not a population-level mortality rate). Active ingredient: No Active Ingredient Defined. Administration routes: Unknown, Oral, Topical.

By species: Dog (27 reports). By breed: Terrier - Black Russian (6), Retriever - Labrador (3), Chihuahua (3).

Leading clinical signs: Bloody diarrhoea (8), Lack of efficacy (ectoparasite) - flea (6), Seizure NOS (5), Lethargy (see also Central nervous system depression in Neurological) (4). Outcome, 27 coded reports: Ongoing leads at 33.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.